2023-08-03 23:30:27 ET
Image source: The Motley Fool.
Geron (NASDAQ: GERN)
Q2 2023 Earnings Call
Aug 03, 2023 , 4:30 p.m. ET
Aron Feingold
For further details see:
Geron (GERN) Q2 2023 Earnings Call Transcript2023-08-03 23:30:27 ET
Image source: The Motley Fool.
Geron (NASDAQ: GERN)
Q2 2023 Earnings Call
Aug 03, 2023 , 4:30 p.m. ET
Aron Feingold
For further details see:
Geron (GERN) Q2 2023 Earnings Call TranscriptMarket Wire News is a media platform, the information on this page was provided by Motley Fool via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
RYTELO, for both RS+ and RS- patients, has a Category 1 recommendation for second-line treatment and a Category 2A recommendation for first-line treatment of patients who are ESA ineligible (serum EPO >500 mU/mL) Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that Anil Kapur, Executive Vice President, Corporate Strategy and Chief Commercial Officer, will depart the Company on August 31, 2024, to ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its second quarter 2024 financial results and business highlights before the market opens on Thursday, August 8, 2024 via press release, which will be available on the Company ...